

# WuXi Biology

## WuXi Biology

### Global Drug Discovery Enabler

- **Comprehensive** discovery and translational biology centers, with **~3,000** experienced scientists and global footprints in **9** sites
- **State-of-the-art** early discovery screening platform, providing diverse hit finding solutions such as DEL/HTS/ASMS/FBDD\* and virtual screening, supported by **cutting-edge** informatics and data sciences
- **Thousands** of validated, 'ready to go', *in vitro* assays and *in vivo* models enabling discovery biology for all target classes, therapeutic areas and modalities
- Extensive **Oncology, Immunology, Infectious Disease, Inflammation, Neuroscience and Metabolic Disease indication**, offering an end-to-end service from discovery, through optimization and into clinical development
- **AAALAC** accredited and **BSL-2** certified small animal and large animal facilities on multiple sites
- **CAP-certified** pathology and FACS capabilities supporting clinical biomarker services

## Services and Solutions

### Early Discovery

- Protein science and crystallography
- Hit identification & screening: FBDD/HTS/DEL/ASMS/VS and libraries for small molecules, covalent, peptides, TPD\* & Macrocycles

### Lead Optimization

- *In vitro* biochemistry and cell biology
- Cell panel screening
- MOA studies
- Radiometric assays
- Clinical biomarker development and validation

### *In Vivo* Pharmacology

- Comprehensive *in vivo* disease model collection
- Targeted oncology and immuno-oncology
- Drug resistance and other novel models of higher translational value
- Tumor model database

\*HTS: High Throughput Screening; DEL: DNA Encoded Library; ASMS: Affinity Selection Mass Spectrometry Screening; FBDD: Fragment-based Drug Discovery; TPD: Targeted Protein Degradation

### By the Numbers



~**3,000** employees worldwide



**9** in **3**  
facilities countries



Entrusted by

**top 15**






global pharmaceutical companies













**1800+**  
customers worldwide

\*Statistics updated as Dec 31, 2023

## Enabling discovery for all modalities

-  Small molecules and peptides
-  Oligonucleotides
-  Bi-functional molecules, e.g. ADC/PDC /POC/TPD(Targeted protein degradation)
-  Vaccines
-  CGT

## Expertise in all major disease areas


-  Oncology & Immunology
-  Cardiovascular Diseases
-  Metabolic Diseases
-  Digestive System
-  Central Nervous System
-  Respiratory Diseases
-  Infectious Diseases
-  Renal Disorders
-  Hepatology
-  Ophthalmology

## A Global Footprint

### CHINA



Shanghai (WGQ)



Shanghai (Zhangjiang)



Suzhou



Nantong



Chengdu


### UNITED STATES



San Diego



Cranbury



Boston / Natick

### GERMANY



Munich

## Contact

### North America

 [mahnaz\\_arjomand@wuxiapptec.com](mailto:mahnaz_arjomand@wuxiapptec.com)  
 +1 415 755 3735



### Europe and Israel

 [dave\\_madge@wuxiapptec.com](mailto:dave_madge@wuxiapptec.com)  
 +44 7803 124321

### China

 [xu\\_longji@wuxiapptec.com](mailto:xu_longji@wuxiapptec.com)  
 +86 185 0210 0621

### Japan

 [fumio\\_itoh@wuxiapptec.com](mailto:fumio_itoh@wuxiapptec.com)  
 +81 75 315 1044

### Korea

 [sycho@wuxiapptec.com](mailto:sycho@wuxiapptec.com)  
 +82 31 724 2861



WuXi Biology website



LinkedIn